Nifuroxazide 965-52-6
Product Description
.cp_wz table {border-top: 1px solid #ccc;border-left:1px solid #ccc; } .cp_wz table td{border-right: 1px solid #ccc; border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;} .cp_wz table th {border-right: 1px solid #ccc;border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;}
Molecular Weight:
275.22 Nifuroxazide is a cell-permeable and orally available nitrofuran-based antidiarrheal agent that effectively suppresses the activation of cellular STAT1/3/5 transcription activity with IC50 of 3 μM against IL-6-induced STAT3 activation in U3A cells
Biological Activity
Nifuroxazide is a nitrofuran compound inhibitor of STAT transcription
factor signaling. Nifuroxazide is described to block constitutive
phosphorylation of STAT3 by reducing Jak kinase autophosphorylation,
decreasing the viability of myeloma cells depending on constitutive
STAT3 activity for survival while not affecting normal peripheral blood
mononuclear cells. Nifuroxazide produces decreases in tyrosine
phosphorylation of Jak2 and Tyk2, and showed no effects on EGF receptor
tyrosine kinase or Src kinase, indicating a relative specificity of
Nifuroxazide for Jak2 and Tyk2. Nifuroxazide shows no inhibition of Akt
or MAPK phosphorylation.
Nifuroxazide inhibits the constitutive
phosphorylation of STAT3 in MM cells by reducing Jak kinase
autophosphorylation, and leads to down-regulation of the STAT3 target
gene Mcl-1. Nifuroxazide causes a decrease in viability of primary
myeloma cells and myeloma cell lines containing STAT3 activation, but
not normal peripheral blood mononuclear cells. Although bone marrow
stromal cells provide survival signals to myeloma cells, nifuroxazide
can overcome this survival advantage. Reflecting the interaction of
STAT3 with other cellular pathways, nifuroxazide shows enhanced
cytotoxicity when combined with either the histone deacetylase inhibitor
depsipeptide or the MEK Inhibitor UO126.
Protocol(Only for Reference)
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Chemical Information
Molarity Calculator
Dilution Calculator
Molecular Weight Calculator
Contact us if you need more details on 965-52-6. We are ready to answer your questions on packaging, logistics, certification or any Other aspects about Nifuroxazide 965-52-6、965-52-6 Nifuroxazide. If these products fail to match your need, please contact us and we would like to provide relevant information.
Molecular Weight:
275.22 Nifuroxazide is a cell-permeable and orally available nitrofuran-based antidiarrheal agent that effectively suppresses the activation of cellular STAT1/3/5 transcription activity with IC50 of 3 μM against IL-6-induced STAT3 activation in U3A cells
Biological Activity
Nifuroxazide is a nitrofuran compound inhibitor of STAT transcription
factor signaling. Nifuroxazide is described to block constitutive
phosphorylation of STAT3 by reducing Jak kinase autophosphorylation,
decreasing the viability of myeloma cells depending on constitutive
STAT3 activity for survival while not affecting normal peripheral blood
mononuclear cells. Nifuroxazide produces decreases in tyrosine
phosphorylation of Jak2 and Tyk2, and showed no effects on EGF receptor
tyrosine kinase or Src kinase, indicating a relative specificity of
Nifuroxazide for Jak2 and Tyk2. Nifuroxazide shows no inhibition of Akt
or MAPK phosphorylation.
Nifuroxazide inhibits the constitutive
phosphorylation of STAT3 in MM cells by reducing Jak kinase
autophosphorylation, and leads to down-regulation of the STAT3 target
gene Mcl-1. Nifuroxazide causes a decrease in viability of primary
myeloma cells and myeloma cell lines containing STAT3 activation, but
not normal peripheral blood mononuclear cells. Although bone marrow
stromal cells provide survival signals to myeloma cells, nifuroxazide
can overcome this survival advantage. Reflecting the interaction of
STAT3 with other cellular pathways, nifuroxazide shows enhanced
cytotoxicity when combined with either the histone deacetylase inhibitor
depsipeptide or the MEK Inhibitor UO126.
Protocol(Only for Reference)
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species | Baboon | Dog | Monkey | Rabbit | Guinea pig | Rat | Hamster | Mouse |
Weight (kg) | 12 | 10 | 3 | 1.8 | 0.4 | 0.15 | 0.08 | 0.02 |
Body Surface Area (m2) | 0.6 | 0.5 | 0.24 | 0.15 | 0.05 | 0.025 | 0.02 | 0.007 |
Km factor | 20 | 20 | 12 | 12 | 8 | 6 | 5 | 3 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Rat dose (mg/kg) = mouse dose (22.4 mg/kg) × | mouse Km(3) | = 11.2 mg/kg |
rat Km(6) |
Chemical Information
Molecular Weight (MW) | 275.22 |
---|---|
Formula | C12H9N3O5 |
CAS No. | 965-52-6 |
Storage | 3 years -20℃Powder |
---|---|
6 months-80℃in solvent (DMSO, water, etc.) | |
Synonyms | |
Solubility (25°C) * | In vitro | DMSO | 55 mg/mL (199.84 mM) |
---|---|---|---|
Water | <1 mg/mL ( | ||
Ethanol | <1 mg/mL ( | ||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Chemical Name | Benzoic acid, 4-hydroxy-, 2-[(5-nitro-2-furanyl)methylene]hydrazide |
---|
Molarity Calculator
Dilution Calculator
Molecular Weight Calculator
Contact us if you need more details on 965-52-6. We are ready to answer your questions on packaging, logistics, certification or any Other aspects about Nifuroxazide 965-52-6、965-52-6 Nifuroxazide. If these products fail to match your need, please contact us and we would like to provide relevant information.
Product Categories : JAK/STAT > STAT inhibitor
Other Products
Hot Products
Astragaloside AChlortetracycline HCl 64-72-2Paclitaxel 33069-62-4Dexamethasone Acetate 1177-87-3Dinaciclib (SCH727965) 779353-01-4CHIR-124 405168-58-3Ro3280 1062243-51-9TAME 901-47-3CCG-1423 285986-88-110058-F4 403811-55-2Dabigatran (BIBR 953) 211914-51-1H 89 2HCl 130964-39-5T0901317 293754-55-9Aprepitant 170729-80-3Turofexorate Isopropyl (XL335) 629664-81-9BMS-378806 357263-13-9